資源描述：
《木香檳榔湯治療便秘型腸易激綜合征（腸道氣滯型）的臨床觀察》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。
1、提要目的：觀察木香檳榔湯治療便秘型腸易激綜合征（C-IBS），中醫(yī)辨證為腸道氣滯型的臨床療效，并初步從理論和臨床研究兩個方面探討木香檳榔湯治療便秘型腸易激綜合征的作用機(jī)理。方法：臨床選擇符合納入標(biāo)準(zhǔn)的便秘型腸易激綜合征患者60例，按隨機(jī)數(shù)字法隨機(jī)分為兩組，治療組（30例）給予木香檳榔湯，對照組（30例）給予六味安消膠囊，兩組均以4個周為一療程。觀察兩組的臨床療效。結(jié)果：臨床研究顯示，治療組中醫(yī)證候療效優(yōu)于對照組（P<0.05）。治療組能明顯改善排便困難、腹痛、腸鳴、噯氣等癥狀以及增加排便頻率等，其療效優(yōu)于對照組（P
2、<0.05）。兩組治療期間均未發(fā)生不良反應(yīng)。結(jié)論：木香檳榔湯是治療腸道氣滯型便秘型腸易激綜合征的有效方劑，能夠消除或改善臨床癥狀，緩解患者的痛苦。關(guān)鍵詞木香檳榔湯；便秘型腸易激綜合征；腸道氣滯；臨床研究TheStudyofMuxiangbinlangtanginTreatingconstipationpredominantIrritableBowelSyndromeinclinicSpeciality：TraditionalmedicineAthour：LiuXueyanTutor：ProfessorLuGuang
3、chaoAbstractObjective：StudytheeffectsofMuxiangbinlangtang（MXBLT）intreatingC-IBSinClinic.Methods：The30patientsofC-IBSweretreatedwithMXBLTandtheclinicaleffectswerecontrastedwiththoseofthe30patientstreatedwithLiuweianxiaoTablet.Symptomsandsignsofeachgroupwereobse
4、rvedbeforeandafterthetreatment.4weekswassetasacourseoftreatment.Theclinicaleffectsofeachgroupwereobservedduring1course.Results：DataoftheclinicalresearchshowedthattheeffectiverateofMXBLTwassignificantlyhigherthanLiuweianxiaoTblet（P<0.05）.Therewassignificantdiff
5、erencebetweenthetreatmentgroupandthecontrolgroup(p<0.05).Conclusions：MuxiangbinlangtangistheeffectiveremedyoftreatingC-IBS，itcanmoderateclinicalsymptoms，promoterecovermentofpathologicalchanges，alleviatethepatients’sufferingsrapidly.KeyWordsMuxiangbinlangtang（M
6、XBLT）；Constipation-predominantirritablebowelsyndrome；Chang-dao-qi-zhi；Clinicalstudy目錄引言...............................................................................................................................1臨床研究.........................................
7、......................................................................................2一、病例選擇.......................................................................................................................2㈠診斷標(biāo)準(zhǔn)..........................................
8、.................................................................................2二、臨床資料............................................................................................
